PTCT stock news · PTC Therapeutics, Inc.
Get alerts for PTCT
Follow PTC Therapeutics, Inc. (PTCT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PTCTWells Fargo says PTC Therapeutics is a good buy and raised its price target to $112.
Good for PTCTWells Fargo kept its favorable rating on PTC Therapeutics and raised its target from $109 to $112. The small increase is a modest positive signal for the company.
PTC Therapeutics raised its money expectations for the whole year of 2026.
Good for PTCTPTC Therapeutics raised its expected 2026 total and product sales ranges. The higher expectations support a stronger outlook for the company.
PTC Therapeutics shares details from their earnings call for the third quarter of 2026.
Good for PTCTPTC Therapeutics raised its 2026 sales forecast after Cephiance sales grew. That points to a stronger outlook, though cash-flow break-even is still expected, not achieved.
PTC Therapeutics enhances its rare disease offerings through the acquisition of 'Unique Opportunity'.
Good for PTCTPTC Therapeutics has announced a strategic acquisition of the ST-920 Fabry disease program from Sangamo Therapeutics, which includes an upfront payment and potential milestone payments. This acquisition is expected to enhance PTC's offerings in the Fabry therapy market and could lead to significant returns on investment, positioning the company favorably in the biotech sector.